House Judiciary Committee Advances Four Drug Pricing Bills, Although Changes Are Still Likely
Executive Summary
US committee will likely re-examine the language regarding the burden of proof in a bill prohibiting pay-for-delay settlements.
You may also be interested in...
California's Pay-For-Delay Law May Be Harsher Than FTC Regulation, Could Face Legal Challenge
Governor Newsom signs bill that presumes brand-generic patent settlements are anticompetitive; AAM says the law violates US Constitution by attempting to regulate transactions outside the state.
Republicans Push Back Against Rx Pricing Transparency Bills At House Hearing
Pricing transparency legislation requests too much information, Republicans say during hearing in US House Energy and Commerce Subcommittee on Health.
Pay-for-Delay Bill Aimed At Blocking Brand/Generic Deals Gets Lower-Than-Expected Savings Estimate
CREATES Act and 180-day exclusivity reforms also in legislation headed to US House floor, even as generic industry remains opposed to two of the three main provisions. The Rx pricing language is bundled with Obamacare language designed to force a tough vote by Republicans.